Celltrion Inc - Company Profile
Powered by 
All the data and insights you need on Celltrion Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Celltrion Inc Strategy Report
- Understand Celltrion Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, and seasonal influenza. Celltrion develops drugs by using its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has an operational presence in Korea, Russia, the UK and the US. Celltrion is headquartered in Incheon, South Korea.
Headquarters
South Korea
Address
23, Academy-Ro, Yeonsu-Gu, Incheon, 22014
Website
www.celltrion.com
Telephone
82 2 16618722
No of Employees
1,074
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
068270 (KRX)
Revenue (2022)
$1.7B
-4.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-0.4%
(2022 vs 2021)
Market Cap*
$29.4B
Net Profit Margin (2022)
XYZ
4.5%
(2022 vs 2021)
* As of and is in US$
Celltrion Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Albothyl | - | - |
| Whituben | Non-GMP Biomanufacturing Service | Truxima |
| Edarbi | cGMP Biomanufacturing Service | Herzuma |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In March, the company announced its plans to acquire Prestige Biologics. |
| 2024 | New Products/Services | In March, Celltrion USA launched a ZYMFENTRA (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab. |
| 2024 | Contracts/Agreements | In January, the company signed a memorandum of understanding with WuXi XDC under which WuXi XDC will provide integrated services for antibody-drug conjugates. |
Competitor Comparison
| Key Parameters | Celltrion Inc | JW Pharmaceutical Corp | Seoul Pharma Co Ltd | ChoongAng Vaccine Laboratory | Biosolution Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Incheon | Gwacheon | Cheongju | Daejeon | Seoul |
| No. of Employees | 1,074 | 1,095 | 176 | 178 | 94 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jin Seok Seo | Chairman | Executive Board | 2021 | 39 |
| Seo Jung-su | Vice Chairman | Executive Board | 2024 | - |
| Woo Sung Kee | Chief Executive Officer; Director | Executive Board | 2023 | 62 |
| Lee Hyeok-jae | Head- Product Development; Director; Managing Director | Executive Board | - | 48 |
| Mincheol Shin | Director; Head- Management Division | Executive Board | 2023 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward